

35. (amended) A method for the inhibition of the inductive effect of beta casein and its fragments on insulin-dependent diabetes in infants and newborns comprising the step of administering to newborns and infants an infant formula comprising at least one casein or fragments thereof selected from the group consisting of naturally occurring, recombinant, synthetic animal or vegetable caseins not containing the sequences: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).

E3 36. A method for the inhibition of the inductive effect of beta casein and its fragments on insulin-dependent diabetes in infants and newborns comprising the administration to newborns and infants a milk which does not contain caseins containing the sequences: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2), said casein being obtained by the following steps: providing a vector suitable for the expression of the casein; transfecting said vector in a cell selected from the group consisting of prokaryotic cell, unicellular eukaryotic cell or a cell derived from a multi cellular organism; and isolating and purifying said casein.

REMARKS

Examiners Crouch and Ton are thanked for their courtesy in granting a personal interview to the inventor and the undersigned on November 21, 2002. The rejections of record were discussed and proposed alternative claim language was also discussed. No agreement was reached as to the allowability of the claims although it was noted that there was no prior art rejection in the last Office Action.

This Amendment is being submitted to present new claims that have been prepared as a result of the interview after a review of the specification and the rejections of record.

Claims 28-36 were rejected under 35 U.S.C. §112, first